Skip to main content

Specialty Pharmacy

  • ProStrakan receives FDA approval to market Rectiv

    GALASHIELS, Scotland, and BEDMINSTER, N.J. — ProStrakan has received approval from the Food and Drug Administration to market an ointment designed to treat moderate to severe pain associated with chronic anal fissures.

    The drug maker, which is a subsidiary of Kyowa Hakko Kirin, said that it received regulatory approval for Rectiv (nitroglycerin) ointment 0.4%. Rectiv currently is the only FDA-approved prescription product for patients with this condition. ProStrakan expects Rectiv to be available in the United States in first quarter 2012.

  • Omnicare adds Mark Emmert, Barry Schochet to board of directors

    COVINGTON, Ky. — Omnicare has added two members to its board of directors.

    The company said that Mark Emmert and Barry Schochet will serve as independent directors. Emmert serves as president of the National Collegiate Athletic Association, while Schochet serves as president and CEO of BPS Health Ventures, a healthcare consulting and investment firm.

  • Axium receives 2011 SMART award from ACG Orlando

    LAKE MARY, Fla. — Axium Healthcare Pharmacy was named the recipient of a 2011 SMART Award in the healthcare and life sciences category by the Association for Corporate Growth's Orlando chapter, the specialty pharmacy provider announced last week.

    Each year, ACG Orlando presents SMART Awards as part of its continuing commitment to facilitate relationships among middle-market companies, capital sources and professionals active in corporate finance throughout Central Florida, Axium said. ACG Orlando hosted its fifth annual SMART Awards luncheon in late May.

  • Abbott receives FDA approval for Lupron Depot

    ABBOTT PARK, Ill. — The Food and Drug Administration has approved a new formulation of an injectable drug made by Abbott for prostate cancer.

    Abbott announced Monday the approval of a 45-mg, six-month formulation of Lupron Depot (leuprolide acetate) for advanced prostate cancer. Previous formulations have allowed patients to receive the drug every month or every three or four months.

  • Specialty Rx, diabetes to drive drug trend

    The overall growth in drug spending for 2010 was 3.7%, according to the latest drug trend report by pharmacy benefit manager Medco Health Solutions. The lower increase 
was primarily due to higher rates of generic drug dispensing — more than 71% of drugs dispensed were generics. 


  • FDA panel unanimously recommends approval of Eylea

    TARRYTOWN, N.Y. — A panel of Food and Drug Administration experts has recommended approval of an investigational biotech drug made by Regeneron Pharmaceuticals for eye diseases.

    Regeneron said Friday that the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee unanimously recommended approval of Eylea (aflibercept) ophthalmic solution for the treatment of a form of age-related macular degeneration, also known as wet AMD. The disease causes abnormal growth of new blood vessels in the eye.

  • Armada inks deal with Emdeon

    FLORHAM PARK, N.J. — Armada Health Care and Emdeon have entered an agreement to support prior authorization management through Armada's ReachRx suite of services, Armada said.

  • FDA approves Nulojix

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for preventing organ rejection in kidney transplant patients, the agency said Wednesday.

    The FDA approved Bristol-Myers Squibb’s Nulojix (belatacept), for preventing acute rejection in adult patients. The drug is approved for use with other immune system-suppressing drugs, specifically Novartis’ Simulect (basiliximab), Genentech’s CellCept (mycophenolate mofetil) and corticosteroids.

X
This ad will auto-close in 10 seconds